F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, bioMérieux SA, are Dominating the Market for Global Immunoassay Reagents and Devices Market in 2019

Immunoassay Reagents and Devices Market is expected to grow at a CAGR of 6.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-immunoassay-reagents-and-devices-market

Global immunoassay reagents and devices market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in global immunoassay reagents and devices market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio. For instance, In July 2019, Bio-Rad Laboratories, Inc. launched Bio-Plex, Pro Human Immunotherapy Panel 20-plex, Multiplex Assay particularly meant for immunotherapy research. This 1 x 96 ready to use kit contains detection antibodies, premixed magnetic capture beads standards, and buffers to enhance the laboratory efficiency. With this launch, company will improve its experimental efficiency by producing key data in a single experiment.  

F. Hoffmann-La Roche Ltd is the dominating player in the immunoassay reagents and devices market which is followed by  Siemens, Randox Laboratories Ltd., Abbott, Bio-Rad Laboratories, Inc., Merck KGaA, Beckman Coulter, Inc (a subsidiary of Danaher), Sysmex Corporation, bioMérieux SA, Thermo Fisher Scientific, Inc, BD, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., DiaSorin S.p.A., Ortho Clinical Diagnostics (a subsidiary of L.L.C), QIAGEN, Quidel Corporation, BioCheck, Inc., Bio-Techne, PerkinElmer Inc, Agilent Technologies, Inc, Luminex Corporation, MESO SCALE DIAGNOSTICS, LLC and others.

F. HOFFMANN-LA ROCHE LTD

F. HOFFMANN-LA ROCHE LTD headquartered in Basel, Switzerland which was founded in 1896. The company is into developing, manufacturing and distributing pharmaceuticals and diagnostics products the business segment of company are pharmaceuticals, diagnostics and market focused is diagnostics. The product categories are pharmaceuticals, solutions for diagnostics, products for researchers and market focused category is solutions for diagnostics.

  • In September 2019, F. Hoffmann-La Roche Ltd received approval from FDA for cobas pro integrated solutions. This approval will help the company to enhance its speed and efficiency in diagnostic solution for improvement in healthcare quality.

The company has wide global presence across the globe such Europe, North America, Asia, Africa, Australia and Oceania. In addition to it, the company also generates its revenue from the various subsidiary companies such Genentech Inc. (U.S.), Roche Diagnostics Limited (U.K.), Chugai Pharmaceutical Co. (Japan), Flatiron Health, Inc. (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc. (U.S.) and others.

Bio-Rad Laboratories, Inc.:

Bio-Rad Laboratories, Inc.  is headquartered in California, U.S. which was founded in 1952. The company is developer and manufacturer of innovative products for the life science research and clinical diagnostic sectors. The business segments of company are life science, clinical diagnostics, other operations and market focused is life science research. The product categories are life science research, clinical diagnostics, spectroscopy, process separations, food science and market focused category is life science research, clinical diagnostics

For instance,

  • In July 2017, Bio-Rad Laboratories, Inc. received FDAapproval for BioPlex 2200 ToRC IgM Assay. This automated assay used to identify IgM group antibodies for cytomegalovirus (CMV) rubella, and Toxoplasma gondii, being presented in a multiplexed panel. With this kit, the company will maximize its laboratory efficiency with a serological profile.

The company has wide global presence across the globe such as Asia-Pacific, Europe, Middle East and Africa, South America, North America. In addition to it, the company also generates its revenue from the various subsidiary companies such as bio-rad abd serotec limited (U.S.), DiaMed Holding AG (Switzerland), QuantaLife, Inc.(U.S.), GnuBIO, Inc.(U.S.) and Bio-Rad Laboratories S.r.l. (U.S.) among others.

bioMérieux SA

bioMérieux SA  has headquartered in Marcy-l'Étoile, France and it was founded in 1963. The company provides in-vitro diagnostics and microbiology testing services for the treatment of various infectious diseases. The product categories are immunoassay, microbiology, molecular diagnostics, performance management, lab automation, pathology and market focused category is immunoassay

  • In November 2019, bioMérieux SA acquired the majority stake of Suzhou Hybiome Biomedical Engineering Co. Ltd. (China). The company developed an immunoassay tests in a more advanced way to deliver high throughput analysis. This acquisition gives bioMérieux SA an opportunity to expand their product portfolio to making it even stronger diagnostic market.

The company has presence in Asia-Pacific, Europe, Middle East and Africa, North America, South America, Oceania. In addition to it, the company also generates its revenue from the various subsidiary companies such as Invisible Sentinel Inc. (France), PML Microbiologicals, Inc. (U.S.), Biomérieux Brasil S.A.(Brazil), Astute Medical, Inc. ( U.S.), BTF Pty Ltd.(France) and others.

Recent Strategic Decisions

Global Immunoassay Reagents and Devices Market